Investigational drug · Phase 2
TAK-341
Also called: MEDI1341
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Multiple System Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "TAK-341"
First trial start
2022
Nov 16, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAK-341", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple System Atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "TAK-341" as an intervention, largest first.
- A Study of TAK-341 in Treatment of Multiple System AtrophyPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05526391 · 158 participants · Start Nov 16, 2022 · Primary completion Jul 28, 2025
Drug: Placebo; TAK-341 · For: Multiple System Atrophy
Sites: Farmington Hills, Michigan; Rochester, Minnesota; New York, New York · 41 sites in all
AstraZenecaAstraZeneca (AZN)
NCT03272165 · 50 participants · Start Oct 17, 2017 · Primary completion Mar 31, 2021
Drug: MEDI1341; Placebo · For: Parkinson's Disease
Sites: Dallas, Texas; Madison, Wisconsin
AstraZenecaAstraZeneca (AZN)
NCT04449484 · 25 participants · Start Aug 4, 2020 · Primary completion Jan 5, 2022
Drug: MEDI1341 · For: Parkinson's Disease
Sites: Long Beach, California; Hallandale, Florida; Atlanta, Georgia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention.
Kniazev R · Cureus 2025
- Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.
Shering C, Pomfret M, Kubiak RJ, et al. · Brain Commun 2025
- An update on immune-based alpha-synuclein trials in Parkinson's disease.
Alfaidi M, Barker RA, Kuan WL · J Neurol 2024
- Immunotherapies for Parkinson's Disease: Progression of Clinical Development.
Teng JS, Ooi YY, Chye SM, et al. · CNS Neurol Disord Drug Targets 2021
- Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
Schofield DJ, Irving L, Calo L, et al. · Neurobiol Dis 2019
Also in development for Multiple System Atrophy
- AmlenetugLu AF82422Phase 32 trials
H. Lundbeck A/S · Multiple System Atrophy
- PBT434ATH434Phase 23 trials
Alterity Therapeutics · Multiple System Atrophy
- Foralumab NasalPhase 22 trials
Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- TEV-56286EmrusolminPhase 22 trials
Teva · Multiple System Atrophy
- exidavnemabPhase 21 trial
BioArctic AB · Parkinson Disease, Multiple System Atrophy
- YA-101Phase 21 trial
Dasher Neuroscience Inc. · Multiple System Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.